

## Letters

### Human Genome Project: Who Will Pay?

In Leslie Roberts' article about the human genome project (Research News, 3 Nov., p. 576), James Watson is quoted as saying that the Japanese are not anteing up with what he considers to be a fair share of the costs of the project and that, if they don't help pay, the results would be handed over for free to the Japanese pharmaceutical industry. The logical question is, What about the American pharmaceutical industry? Why is there no effort to have these companies pay for part of the research? For many years now, industry has been riding a gravy train, in which government in effect subsidizes them by paying for university and medical school basic biological research, the commercial benefits of which accrue to industry. Because of the huge costs of the genome project, now is the correct time to ask industry to pay up, not to have the taxpayers take all the risk without any of the commercial benefits.

PHILIP SIEKEVITZ  
Rockefeller University,  
1230 York Avenue,  
New York, NY 10021-6399

### HIV, Drugs, and Ecology

Don C. Des Jarlais and Samuel R. Friedman (Perspective, 11 Aug., p. 578) discuss the significance of intravenous drug users (IVDUs) in determining the magnitude of the human immunodeficiency virus (HIV)/AIDS epidemics in Europe and in the United States. IVDUs contribute directly to the number of AIDS cases and also indirectly by infecting their non-IVDU sex partners through sexual transmission and their children through perinatal transmission. The authors mention that cross-national sampling studies of IVDUs are beginning and that such studies are necessary to evaluate the effects of intervention strategies. We agree that such studies are essential, but we wish to stress that sampling studies do not address the question, What is the size of the IVDU community? The future number of AIDS cases cannot be accurately assessed unless the size of the IVDU community can be reasonably estimated.

Ecologists have developed a considerable number of techniques for estimating animal population sizes, and such techniques may be used to estimate the size of the IVDU

community. One such technique (mark-recapture) involves capturing, marking, and recapturing (on a second visit) a subject of the study population (1). The simplest "mark-recapture" model was used to estimate the number of IVDUs in New York City in 1970 (1). This estimate was then extrapolated by regression analysis to provide an estimate of 200,000 IVDUs in 1978 (2). The outdated estimate of 200,000 IVDUs is still being used by the Health Department of New York City to calculate the present number of infected IVDUs (3). The original estimate was calculated on the basis of data from a pre-1968 cohort and may be extremely inaccurate, due both to the simplicity of the model used and to sampling biases inherent in the data base from which the sample data were derived. The estimation of 200,000 IVDUs by regression analysis is based on indicator variables; the stability and validity of these indicator variables have not yet been established.

It is clearly necessary to sample IVDUs and to quantify their intravenous drug use and their sexual behavior. However, it is also essential to estimate the current population size of the IVDU community, in New York City and elsewhere, in order to prepare adequate public health planning.

SALLY BLOWER\*  
Parasite Epidemiology Research Group,  
Department of Pure and Applied Biology,  
Imperial College of Science, Technology and  
Medicine,  
Prince Consort Road, London SW7 2BB,  
England

DIANA HARTEL  
Montefiore Medical Center,  
111 East 210th Street,  
Bronx, NY 14067

#### REFERENCES AND NOTES

1. For an IVDU population, names can be used as unique identifiers, and admission lists for certain institutions (for example, hospital emergency rooms) can be regarded as capture data.
2. B. Frank, J. Schmeidler, B. Johnson, D. S. Lipton, *Drug Alcohol Depend.* 3, 345 (1978).
3. *Estimate of HIV-Infected New Yorkers* (Working Pap., New York City Department of Health, New York, July 1988).

\*Present address: Gertrude H. Sergievsky Center, Columbia University, 630 West 168th Street, New York, NY 10032.

### Space Station

Who can justify the Space Station? The American Geophysical Union has said that it cannot provide a scientific justification. Is any other scientific or engineering society prepared to provide a justification? If the justification is prestige, who's prepared to

identify what step the Space Station will make that others will not have already made? It's high time that whoever wants the Space Station provide a justification for the massive resources it will require for decades.

L. H. MEREDITH  
Group Director,  
American Geophysical Union,  
2000 Florida Avenue, NW,  
Washington, DC 20009

### Transportation Subsidy Policy

Martin Wachs' review (Articles, 30 June, p. 1545) of U.S. transit subsidy policy is an exercise in advocacy; an advocacy that ignores external costs, federal taxation policies, local government land use policies, and hidden public and private subsidies. Like any piece of advocacy, its questions and premises appear to be narrowed.

Wachs operates from the premise that increased automobile ownership and decentralization of both residences and places of employment are environmental givens; he does not seem to be saying that they are immutable societal trends, but that they are not about to be changed in America. He discounts evidence from Canada, Japan, and Europe that shows government policy to be a more profound influence on land use and transportation choices than are national wealth or access to open space. His most telling example is that the federal investment in transit has only been able to level off the decline in transit ridership, not increase it.

His example shows that a narrow approach to transportation will not work; funding transit but undermining it with massive roadway, tax, and parking subsidies to auto users is not an optimizing approach. Supporting these auto subsidies with auto-oriented zoning regulations is even worse. This has created a "looking-glass" situation in which American governments have had to run faster just to stay in place. In Europe, where auto users are not subsidized, the per capita transit subsidy is lower than in America. European governments provide a far more commodious, frequent, and reliable transit service to their constituents, but they do not have to overcome self-made obstacles.

Wachs dismisses the European and Canadian examples politically. He says that American government is not likely to reorient to an interrelated land-use, taxation, and subsidy policy because of entrenched interests. He is wrong at the local level, and there is hope that he may be wrong at the federal level. More cities are becoming interested in tying parking and other land-use issues to